Biogen Inc Stock Analysis

Biogen Stock Analysis Notes

About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biogen Inc recorded earning per share (EPS) of 10.97. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 18th of January 2001. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people. For more info on Biogen Inc please contact Christopher Viehbacher at 617 679 2000 or go to https://www.biogen.com.

Biogen Inc Investment Alerts

Biogen Largest EPS Surprises

View All Earnings Estimates

Biogen Environmental, Social, and Governance (ESG) Scores

Biogen Thematic Classifications

Biogen Stock Institutional Investors

Note, although Biogen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biogen Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 27.19 B.

Biogen Profitablity

The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.31 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.31.

Management Efficiency

Biogen Inc has return on total asset (ROA) of 0.0575 % which means that it generated a profit of $0.0575 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0931 %, meaning that it created $0.0931 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 24.9 B, whereas Net Tangible Assets are forecasted to decline to about 4.1 B.

Technical Drivers

As of the 6th of February, Biogen shows the Risk Adjusted Performance of 0.1224, downside deviation of 1.85, and Mean Deviation of 1.42. Biogen Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Biogen Inc Price Movement Analysis

Biogen Inc Insider Trading Activities

Biogen Outstanding Bonds

Biogen Predictive Daily Indicators

Biogen Corporate Filings

Biogen Forecast Models

Biogen's time-series forecasting models are one of many Biogen's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biogen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Biogen Bond Ratings

Biogen Inc financial ratings play a critical role in determining how much Biogen have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Biogen's borrowing costs.

Biogen Inc Debt to Cash Allocation

Biogen Inc currently holds 6.63 B in liabilities with Debt to Equity (D/E) ratio of 0.52, which is about average as compared to similar companies. Biogen Inc has a current ratio of 2.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biogen's use of debt, we should always consider it together with its cash and equity.

Biogen Total Assets Over Time

Biogen Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Biogen uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Biogen Debt Ratio

11.0

It appears most of the Biogen's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Biogen's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Biogen, which in turn will lower the firm's financial flexibility.

Biogen Corporate Bonds Issued

Biogen Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biogen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biogen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Biogen. By using and applying Biogen Stock analysis, traders can create a robust methodology for identifying Biogen entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biogen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biogen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Biogen Inc stock analysis indicators help investors evaluate how Biogen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biogen shares will generate the highest return on investment. By understating and applying Biogen stock analysis, traders can identify Biogen position entry and exit signals to maximize returns.

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.